Journal of Biomedical and Pharmaceutical Research
Available Online at www.jbpr.in
CODEN: - JBPRAU (Source: - American Chemical Society)
NLM (National Library of Medicine): ID: (101671502)
Index Copernicus Value 2023: 85.868
Volume 14, Issue 4; 2025, 01-17
ISSN (Online): 2279-0594
ISSN (Print): 2589-8752

Review Article

A Review on Nephrotoxicity of Herbal and Traditional Medicines: A Growing Public Health Concern

Md. Rahat Mujib[1], Manish Kumar[2], Aditya Kumar[3]
[1] B. Pharm 4th year Student, Krishna Institute of Nursing & Paramedical Science, Samastipur, Bihar
[2,3] Faculty of Krishna Institute of Nursing & Paramedical Science, Samastipur, Bihar

Article Info: Received: 05-05-2025 / Revised: 27-05-2025 / Accepted: 30-06-2025
Corresponding Author: Md. Rahat Mujib
DOI: https://doi.org/10.32553/jbpr.v14i4.1326
Conflict of interest statement: No conflict of interest

Abstract:
Herbal and traditional medicines are widely used globally for their therapeutic and cultural significance. However, mounting evidence indicates a significant risk of nephrotoxicity associated with various unregulated herbal formulations. This review explores the multifaceted impact of herbal and traditional medicines on renal health, detailing mechanisms of toxicity, commonly implicated herbs, vulnerable populations, clinical case studies, and existing gaps in regulatory oversight. Special emphasis is given to the rising incidence of acute kidney injury (AKI) and chronic kidney disease (CKD) linked to herbs such as *Aristolochia*, *Aloe vera*, and heavy metal-containing Ayurvedic preparations. The article also presents a comprehensive literature review, highlighting both global and region-specific trends. It critically examines current regulatory practices, identifies challenges in herbal pharmacovigilance, and outlines actionable strategies for prevention. These include public education, toxicovigilance systems, physician training, and labeling reforms. The review concludes with recommendations for future research, including the use of artificial intelligence (AI), global policy harmonization, and integrative approaches to minimize renal toxicity while preserving the beneficial aspects of traditional medicine. Ensuring the safety of herbal therapies is a pressing public health priority that demands collaborative and multidisciplinary interventions.
Keywords: Herbal nephrotoxicity; Traditional medicine; Acute kidney injury (AKI); Chronic kidney disease (CKD); Aristolochic acid; Herbal pharmacovigilance; Public health; Regulation; Ayurveda; Toxicovigilance; Herb–drug interactions

1.1 Introduction

The use of herbal and traditional medicines has witnessed an upsurge in the 21st century, particularly in developing nations where access to modern medicine may be limited. Even in developed nations, a growing number of individuals are turning toward alternative and complementary therapies due to perceptions of safety and natural origin. However, the nephrotoxic potential of these remedies has emerged as a major public health concern. Nephrotoxicity refers to the toxic impact of substances on the kidneys, which are vital organs responsible for maintaining fluid and electrolyte balance, detoxification, and waste elimination [1].

The World Health Organization (WHO) estimates that over 80% of the global population relies on traditional medicine for primary healthcare needs [2]. While many herbal remedies may offer therapeutic benefits, a lack

of standardization, incorrect dosing, contamination with heavy metals, and the presence of nephrotoxic phytochemicals present significant risks.

1.2 Kidney Function and Importance

The kidneys play a pivotal role in the human body by filtering approximately 180 liters of blood daily and excreting metabolic waste through 1.5 liters of urine [3]. They are involved in vital processes such as:

- Regulation of fluid and electrolyte balance
- Acid-base homeostasis
- Blood pressure control via the renin-angiotensin-aldosterone system
- Erythropoietin production for red blood cell formation
- Drug metabolism and excretion

Due to their rich blood supply and active transport mechanisms, kidneys are particularly susceptible to damage from toxic substances, including phytochemicals found in some herbal medicines [4].

1.3 Rise in Herbal Medicine Usage

In recent decades, there has been a resurgence in the popularity of herbal medicine. Some of the driving factors include:

- Cultural beliefs and traditional practices
- Perception that "natural" equals "safe"
- Limited access to conventional healthcare
- Aggressive marketing of herbal products as dietary supplements

While many herbal products are safe when used correctly, the growing trend of self-medication and use of polyherbal formulations without medical supervision has increased the risk of adverse effects, including nephrotoxicity [5].

1.4 Nephrotoxicity in Herbal and Traditional Medicines

Nephrotoxicity can manifest in various forms depending on the toxic agent, dose, duration, and individual susceptibility. Herbal medicines may induce:

- Acute kidney injury (AKI)
- Chronic kidney disease (CKD)
- Tubular necrosis
- Interstitial nephritis
- Renal fibrosis

Several herbs such as Aristolochia spp., Tripterygium wilfordii, Aloe vera, and Glycyrrhiza glabra (licorice) have been implicated in renal damage. Aristolochic acid, a potent nephrotoxin and carcinogen found in Aristolochia species, has been associated with Balkan endemic nephropathy and Chinese herb nephropathy [1,3].

1.5 Pathways of Toxicity

There are several mechanisms by which herbal components can damage the kidneys:

- Direct cytotoxicity to renal tubular epithelial cells
- Generation of reactive oxygen species (ROS) and oxidative stress
- Immune-mediated reactions, including glomerulonephritis
- Crystal nephropathy due to oxalate accumulation
- Hemodynamic alterations, leading to ischemic injury

These mechanisms often culminate in compromised renal function, which may be reversible or progressive depending on early recognition and withdrawal of the offending agent.

1.6 Challenges in Regulation

A major contributor to the nephrotoxicity risk is the lack of stringent regulation in many countries. Herbal products are often marketed as food supplements, exempt from the rigorous testing required for pharmaceuticals. Common regulatory gaps include:

- Lack of quality control during manufacturing
- Adulteration with pharmaceuticals (e.g., NSAIDs, steroids)
- Misidentification of plant species
- Inadequate labeling and dosing information

In countries like India and China, traditional systems such as Ayurveda and Traditional Chinese Medicine (TCM) are officially recognized, but oversight for safety remains inconsistent across products [2].

1.7 Polyherbal Formulations and Interactions

Polyherbal formulations are complex mixtures containing multiple herbs, increasing the risk of

herb-herb or herb-drug interactions. For instance:

- St. John's Wort induces cytochrome P450 enzymes, potentially reducing the efficacy of co-administered drugs.
- Licorice may cause hypokalemia and hypertension, exacerbating renal injury in susceptible individuals.
- Diuretic herbs such as dandelion may alter fluid and electrolyte balance, stressing renal function further [5].

Additionally, interactions with conventional medications—such as antihypertensives, antibiotics, or antidiabetics—may compound nephrotoxicity risk.

1.8 Public Health Implications

The growing prevalence of chronic kidney disease globally (estimated at ~10% of the adult population) is further burdened by nephrotoxic exposures from herbal sources [3]. Misguided trust in herbal therapies may delay proper diagnosis and treatment of renal dysfunction, often until irreversible damage occurs.

There is an urgent need for:

- Greater awareness among the public and healthcare providers
- Active surveillance and reporting systems
- Comprehensive research on herbal renal safety
- Development of national guidelines and policy frameworks

Table 1: Common Herbal Agents Implicated in Nephrotoxicity

Herbal Agent	Toxic Component	Associated Renal Effect	References
Aristolochia spp.	Aristolochic acid	Interstitial fibrosis, CKD	[1]
Tripterygium wilfordii	Triptolide	AKI, tubular necrosis	[2]
Aloe vera (high doses)	Anthraquinones	Tubulointerstitial nephritis	[3]
Glycyrrhiza glabra	Glycyrrhizin	Hypokalemia, rhabdomyolysis, AKI	[4]
Teucrium chamaedrys	Neoclerodane diterpenes	Hepatorenal syndrome	[5]



Fig.1 Global herbal medicine usage statistics by region

Chapter 2: Mechanisms of Herbal-Induced Nephrotoxicity

2.1 Introduction

The kidneys are particularly susceptible to xenobiotic injury due to their role in filtration, active transport, and concentration of toxins. Herbal medicines, though natural in origin, contain bioactive phytochemicals that may exert toxic effects via multiple renal pathways. Understanding the mechanistic basis of nephrotoxicity is essential for risk evaluation and clinical decision-making.

Herb-induced nephrotoxicity involves both direct cytotoxic and immune-mediated mechanisms. These may lead to acute kidney injury (AKI), chronic kidney disease (CKD), or irreversible end-stage renal disease (ESRD), depending on exposure and host susceptibility [15].

2.2 Direct Cytotoxic Effects

2.2.1 Tubular Epithelial Injury

Many nephrotoxic herbs induce damage through direct toxic effects on the renal tubular epithelial cells. Compounds such as triptolide (from *Tripterygium wilfordii*) and anthraquinones (from Aloe species) have been shown to trigger apoptosis and necrosis in proximal tubular cells by inhibiting mitochondrial function and causing ATP depletion [16].

Triptolide, in particular, has been shown to:

- Disrupt mitochondrial membrane potential
- Activate caspase-3 pathways
- Promote oxidative DNA damage in renal cells [17]

2.2.2 Reactive Oxygen Species (ROS) and Oxidative Stress

Herbal toxins often elevate ROS production, leading to oxidative stress, lipid peroxidation, and DNA damage in nephrons. For example, aristolochic acid triggers ROS-mediated fibrosis via TGF-β signaling and upregulation of pro-fibrotic cytokines [18].

Patients with poor antioxidant defenses (e.g., elderly or malnourished individuals) are particularly vulnerable to such damage.

2.3 Immunoallergic Mechanisms

Certain herbal medicines can stimulate immune-mediated responses, resulting in interstitial nephritis, a type of hypersensitivity reaction characterized by:

- Infiltration of inflammatory cells (eosinophils, mononuclear cells)
- Tubular injury
- Interstitial edema

This is common with Teucrium chamaedrys and herbal preparations contaminated with NSAIDs or heavy metals. The pathophysiology involves delayed-type hypersensitivity and immune complex deposition, which may evolve into chronic inflammation and fibrosis [19].

2.4 Hemodynamic Alterations

Some herbs act as natural diuretics or vasodilators, disrupting the renal autoregulation of blood flow. For instance:

- Licorice (Glycyrrhiza glabra) inhibits 11β-HSD2, leading to increased cortisol levels that act on mineralocorticoid receptors.
- This induces sodium retention, potassium loss, and volume expansion, ultimately impairing glomerular filtration [20].

In predisposed individuals (e.g., hypertensives), such volume changes can lead to acute renal ischemia.

2.5 Crystal Nephropathy and Obstructive Uropathy

Some herbal constituents are rich in oxalates, which may precipitate within renal tubules, causing crystal nephropathy. For example, large doses of rhubarb root (*Rheum palmatum*) or star fruit (*Averrhoa carambola*) have been implicated in oxalate-induced nephropathy.

Crystal formation can lead to:

- Obstruction of nephron segments
- Inflammatory cell infiltration
- Progressive tubulointerstitial fibrosis [21]

2.6 Heavy Metal-Induced Nephropathy

Ayurvedic and Siddha formulations may be contaminated with lead, mercury, arsenic, or cadmium during preparation or storage. These heavy metals are nephrotoxic, particularly to the proximal tubules, and result in:

- Glomerular sclerosis
- Tubular atrophy
- Proteinuria and hypertension [22]

Chronic exposure can lead to Fanconi syndrome, where the reabsorptive capacity of the proximal tubules is severely impaired.

2.7 Synergistic Toxicity and Polyherbal Effects

Polyherbal formulations may contain multiple bioactive compounds that interact to produce cumulative or synergistic toxicity. Moreover, the combination of herbs with prescribed nephrotoxic drugs (like aminoglycosides, diuretics, or NSAIDs) may potentiate renal injury.

For example:

- Aristolochia combined with NSAIDs amplifies renal tubular necrosis risk [23].
- Herbal diuretics may dehydrate patients, concentrating nephrotoxins further.

2.8 Epigenetic and Fibrotic Pathways

Recent studies suggest that some herbal toxins modulate epigenetic regulators such as DNA methylation and histone acetylation, leading to:

- Persistent activation of TGF-β/Smad signaling
- Fibroblast-to-myofibroblast transition
- Collagen deposition and scarring [24]

These molecular changes are difficult to reverse and contribute to progression from AKI to CKD.

Table 2: Mechanisms of Nephrotoxicity Induced by Common Herbal Agents

Herbal Agent	Key Toxin	Mechanism of Renal Injury	Reference
Aristolochia spp.	Aristolochic acid	DNA adducts, ROS generation, fibrosis	[18]
Tripterygium wilfordii	Triptolide	Mitochondrial damage, apoptosis	[17]
Aloe vera	Anthraquinones	Tubular necrosis, oxidative stress	[16]
Glycyrrhiza glabra	Glycyrrhizin	RAAS interference, volume overload	[20]
Ayurvedic Rasayanas	Lead, mercury	Heavy metal-induced tubular dysfunction	[22]
Teucrium chamaedrys	Diterpenoids	Immunoallergic interstitial nephritis	[19]
Rheum palmatum	Oxalates	Crystal nephropathy, tubular obstruction	[21]



Fig 2. Pathways of herbal-induced nephrotoxicity (e.g., oxidative stress, tubular necrosis)

Chapter 3: Case Studies and Country-Specific Examples

3.1 Introduction

The global landscape of herbal medicine usage reflects diverse traditional practices. However, the unregulated or improper use of these remedies has led to multiple documented cases of nephrotoxicity across different regions. This chapter reviews key clinical case studies and country-specific examples to provide insights into the practical impact of nephrotoxic herbal exposure and how cultural, socioeconomic, and regulatory factors contribute to this growing burden.

3.2 India: Ayurveda and Heavy Metal Toxicity

India, a hub of traditional systems like Ayurveda, Unani, and Siddha, has documented numerous instances of renal injury due to polyherbal formulations and Rasa Shastra-based preparations. These often contain heavy metals such as lead, mercury, and arsenic, sometimes purposefully included for therapeutic effects.

Case Example:

A 52-year-old male presented with elevated serum creatinine and symptoms of fatigue after using an Ayurvedic product for diabetes. Toxicological analysis revealed lead levels five times above normal and nephrotic-range proteinuria. Renal biopsy showed chronic interstitial nephritis. Chelation therapy was initiated, with partial improvement in renal function [25].

In another hospital-based study in Delhi, 15.2% of CKD patients reported using traditional herbal medications, and nearly half of them contained high levels of nephrotoxic metals [26].

3.3 China: Aristolochic Acid and Urothelial Cancer

Traditional Chinese Medicine (TCM) has long used plants like *Aristolochia fangchi* under the name *Mu Tong*. However, this herb contains aristolochic acid, a proven nephrotoxin and carcinogen.

Epidemic Example:

The most notable case occurred in Belgium (but linked to Chinese herbs) in the early 1990s. Over 100 women attending a slimming clinic developed rapidly progressive interstitial nephritis, later named Chinese herb nephropathy. Many required dialysis or renal transplantation. The herbal pills were found to contain *Aristolochia fangchi*, misidentified during manufacturing [27].

Following the incident, a Taiwan-based population study confirmed that over 12,000 individuals exposed to aristolochic acid had significantly increased risk of ESRD and urothelial carcinoma [28].

3.4 Africa: Traditional Healing and Acute Kidney Injury

In sub-Saharan Africa, the use of traditional medicine is deeply embedded in the healthcare system. However, poor regulation and lack of standardization contribute to nephrotoxicity.

Community Case Series:

In Nigeria, a survey among AKI patients revealed that 35% had consumed native herbal mixtures for fever and malaria, which included unknown plant species and high doses. Laboratory tests confirmed elevated creatinine and urea, with imaging showing renal cortical necrosis in several cases [29].

In Tanzania, herbal concoctions used for postpartum care were found to cause AKI in 18% of maternal ICU admissions [30].

3.5 Middle East: Use of Herbal Laxatives and Supplements

In Iran and neighboring countries, herbal laxatives such as senna, rhubarb, and cascara sagrada are commonly used for digestive issues. These herbs contain anthraquinones, which can lead to chronic interstitial nephritis on long-term use.

Case Insight:

A retrospective review of nephrology cases in Tehran found that 9% of CKD cases had chronic exposure to senna-based laxatives. Renal biopsies revealed tubular atrophy and interstitial fibrosis consistent with toxic nephropathy [31].

3.6 Latin America: Indigenous and Homeopathic Practices

In Latin America, traditional medicine is often practiced alongside Western medicine. Indigenous herbs such as chaparral, comfrey,

and uňa de gato (cat's claw) have been implicated in renal toxicity.

Case Study:

A woman in Brazil developed oliguric AKI after ingesting concentrated cat's claw extract for arthritis. Renal biopsy confirmed acute tubular necrosis. She recovered partially with supportive therapy but remained hypertensive with stage 3 CKD [32].

3.7 Western Countries: Over-the-Counter Herbal Supplements

Although herbal medicine is not traditionally embedded in Western healthcare, dietary supplements are widely used. Many contain unlisted ingredients, are contaminated, or interact with prescribed drugs.

Example from the USA:

A 65-year-old woman presented with fatigue, edema, and rising creatinine. She had been self-administering a weight-loss supplement from an online vendor. Toxicology identified aristolochic acid, likely from *Aristolochia*-containing ingredients. Her renal function deteriorated rapidly, and she progressed to dialysis-dependent ESRD [33].

3.8 Summary of Key Case Studies and Countries

The evidence from diverse geographical regions emphasizes a clear link between herbal medicine use and renal damage. The form of toxicity may vary—from acute, reversible injury to chronic, irreversible disease—and is influenced by the type of herb, mode of preparation, and regulatory environment.

Table 3: Global Case Studies of Herbal-Induced Nephrotoxicity

Country	**Herbal Product**	**Renal Effect**	**Reference**
India	Ayurvedic Rasayana (lead)	Chronic interstitial nephritis	[25]
China/Taiwan	*Aristolochia spp.*	Interstitial fibrosis, urothelial CA	[27], [28]
Nigeria	Traditional fever remedies	Acute tubular necrosis	[29]
Tanzania	Postpartum care herbs	AKI, ICU admission	[30]
Iran	Senna-based laxatives	Tubular atrophy, CKD	[31]
Brazil	Cat's claw extract	Acute tubular necrosis	[32]
USA	Online weight-loss supplement	Aristolochic acid nephropathy	[33]

Fig.3 Senna

Chapter 4: Risk Factors and Vulnerable Populations

4.1 Introduction

Although herbal and traditional medicines are used across various demographics, certain populations are disproportionately affected by their nephrotoxic effects. This chapter focuses on identifying these vulnerable groups and the risk factors that exacerbate susceptibility to renal damage from herbal agents. Understanding these risks is vital for clinicians, policymakers, and researchers seeking to develop preventive and therapeutic strategies.

4.2 Elderly Population

The elderly represent a major at-risk population due to age-related decline in renal function, polypharmacy, and a higher prevalence of chronic diseases like diabetes and hypertension.

Contributing Factors:

- Reduced glomerular filtration rate (GFR)
- Altered drug metabolism and clearance
- Concurrent use of nephrotoxic drugs (e.g., NSAIDs, ACE inhibitors)

A study in Taiwan reported that individuals over the age of 65 using Chinese herbal medicines had a 2.5-fold higher risk of developing chronic kidney disease compared to non-users [34].

4.3 Patients with Pre-existing Renal Disease

Patients already diagnosed with CKD are extremely susceptible to further nephrotoxicity from herbal products.

Clinical Example:

A case-control study from India revealed that CKD patients who consumed unregulated herbal remedies for blood sugar control had significantly faster decline in eGFR compared to those who did not [35].

Herbs such as Aristolochia spp., Triphala, and metal-containing Ayurvedic drugs can accelerate progression from early-stage CKD to ESRD when used without supervision.

4.4 Pregnant and Postpartum Women

Pregnancy is a physiologically sensitive period. Many cultures administer herbal preparations to promote labor, cleanse the uterus, or treat postpartum ailments. Unfortunately, several of these traditional remedies carry nephrotoxic potential.

Risk Factors:

- Volume depletion due to diuretic herbs
- Contaminated remedies leading to AKI
- Unmonitored polyherbal use with unknown safety profiles

A Tanzanian study showed that 18% of postpartum AKI cases were associated with traditional remedies consumed after childbirth [30].

4.5 Paediatric Population

Children are vulnerable due to immature renal systems and metabolic pathways. Herbal remedies for colic, teething, and common infections are often used without dosage consideration.

Example:

In Nigeria, over 30% of paediatric AKI admissions were linked to herbal mixtures given by caregivers. These included preparations with unknown plant sources and toxic concentrations [36].

4.6 Individuals with Low Health Literacy

Limited awareness about the potential risks of herbal medicines leads many users to consume them as “safe alternatives” to pharmaceuticals.

Contributing Issues:

- Belief in the “natural = safe” myth
- Lack of label information or professional guidance
- Misconceptions fuelled by informal advertisements

Surveys conducted in rural India and Latin America showed that 60–75% of herbal users believed traditional remedies had no side effects, despite adverse outcomes [37].

4.7 Concomitant Use with Prescription Drugs

The co-administration of herbal and modern pharmaceuticals increases the likelihood of herb–drug interactions. These interactions can exacerbate nephrotoxicity via:

- Additive renal injury (e.g., NSAIDs + nephrotoxic herbs)
- Altered pharmacokinetics (inhibition/induction of drug-metabolizing enzymes)

For instance, using Aloe vera laxatives with diuretics or ACE inhibitors can lead to volume depletion and hypoperfusion-related AKI [38].

4.8 Cultural and Economic Influences

Traditional medicines are more accessible and affordable for rural and low-income communities. This reliance, though often necessary, contributes to higher exposure risks.

Key Drivers:

- Cost of allopathic treatment
- Cultural belief systems and ancestral traditions
- Trust in local healers over healthcare providers

In Latin America and parts of Africa, more than 70% of the population uses traditional remedies as first-line treatment due to cost and accessibility [39].

Table 4: Key Risk Factors and Vulnerable Populations for Herbal-Induced Nephrotoxicity

Vulnerable Group	Risk Factors	Reference
Elderly	Age-related GFR decline, polypharmacy	[34]
CKD Patients	Reduced renal reserve, herb-drug interaction	[35]
Pregnant/Postpartum Women	Use of uterotonic or diuretic herbs	[30]
Children	Immature kidney development, unsupervised usage	[36]
Low Literacy Users	Misinformation, cultural beliefs, lack of regulation	[37]
Polypharmacy Patients	Synergistic toxicity, altered drug metabolism	[38]
Economically Disadvantaged	Accessibility, affordability, trust in traditional healers	[39]

Chapter 5: Regulatory Landscape and Policy Implications

5.1 Introduction

Despite the widespread use of herbal and traditional medicines, regulation of their safety, efficacy, and quality remains inconsistent globally. Many herbal products bypass stringent testing, resulting in an underrecognized public health burden, particularly nephrotoxicity. This chapter explores the current regulatory landscape, identifies gaps in oversight, and offers policy-based solutions for improving herbal medicine safety.

5.2 Global Regulatory Frameworks: A Fragmented Approach

5.2.1 World Health Organization (WHO)

The WHO Traditional Medicine Strategy 2014–2023 advocates integrating traditional medicine into national healthcare systems while emphasizing safety, quality, and efficacy [40]. However, implementation varies widely between countries due to differences in resources, political will, and cultural practices.

5.2.2 United States (FDA)

In the United States, herbal supplements are regulated under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Under this act:

- Herbal products are considered dietary supplements.
- Manufacturers are responsible for ensuring safety but not required to prove efficacy or undergo pre-market approval [41].

This loophole has resulted in adulterated or misbranded herbal products entering the market, contributing to adverse renal events.

5.2.3 European Union (EMA)

The European Medicines Agency (EMA) offers two regulatory pathways:

1. Well-established use authorization
2. Traditional use registration (must show 30 years of use, including 15 years in the EU)

While more stringent than the US, the EMA still faces challenges with imports and online sales of unregistered products [42].

5.3 Country-Specific Gaps in Regulation

5.3.1 India

India's AYUSH (Ayurveda, Yoga, Unani, Siddha, Homeopathy) systems are governed by the Ministry of AYUSH. However:

- Many formulations are marketed without clinical trials.

- Quality control of raw herbs is poorly standardized.
- Surveillance of adverse effects is minimal [43].

5.3.2 China

China regulates Traditional Chinese Medicine (TCM) under the State Administration of Traditional Chinese Medicine. While efforts have improved post-marketing surveillance, aristolochic acid-containing products were not banned until years after global nephrotoxicity outbreaks [44].

5.3.3 Africa and Latin America

In many African and Latin American nations, herbal remedies are unregulated or treated as food products. Vendors are often untrained, and labeling is minimal or absent. This regulatory vacuum facilitates the sale of nephrotoxic and contaminated herbal products [45].

5.4 Surveillance Systems and Pharmacovigilance

5.4.1 Lack of Herbal Adverse Event Reporting

Herbal pharmacovigilance is still in its infancy. National adverse event databases rarely include herbal products, and most nephrotoxicity cases go unreported or misattributed.

An analysis of the US FDA Adverse Event Reporting System (FAERS) showed that less than 5% of herbal-induced kidney injuries were formally reported over a 10-year period [46].

5.4.2 Inadequate Toxicological Evaluation

Preclinical testing of herbal medicines is not mandated in many jurisdictions. Toxicity data, including nephrotoxicity studies, are often absent or unpublished, especially for complex polyherbal formulations.

5.5 Challenges in Regulation

Challenge	Implication
No standardized global definitions	Difficulty in harmonizing safety standards
Incomplete labelling	Undisclosed nephrotoxins, heavy metals
Online and cross-border sales	Import of unregulated, adulterated products
Polyherbal formulations	Complex interactions, difficult toxicity prediction
Weak enforcement of penalties	Repeat violations by companies and manufacturers

5.6 Policy Recommendations

5.6.1 Strengthening Pre-market Evaluation

- Mandate toxicological screening, including nephrotoxicity testing.
- Require clinical trial data for new herbal formulations.

5.6.2 Clear Labelling and Dosage Information

- Display active ingredients, known side effects, and usage warnings.
- Include information on renal safety, especially for vulnerable populations.

5.6.3 Global Harmonization of Standards

- Develop an international framework via WHO or International Council for Harmonisation (ICH) for herbal medicine regulation.
- Promote inter-country data sharing on adverse events.

5.6.4 Enhancing Pharmacovigilance

- Integrate herbal products into national adverse drug event reporting systems.
- Establish dedicated herbal pharmacovigilance units.

5.6.5 Education and Awareness

- Train healthcare providers on identifying and reporting herbal nephrotoxicity.
- Educate the public about potential kidney risks from “natural” products.

Table 5. Comparative Summary of Herbal Medicine Regulation

Region/Country	Regulatory Body	Pre-market Approval Required?	Herbal Nephrotoxicity Surveillance	Reference
WHO	WHO Traditional Medicine Strategy	No	Encouraged (country dependent)	[40]
USA	FDA (DSHEA)	No	Minimal	[41], [46]
EU	EMA	Yes (in specific categories)	Moderate	[42]
India	Ministry of AYUSH	Partially	Weak	[43]
China	State Admin. of TCM	Yes (recent improvement)	Improving	[44]
Africa/Latin America	Varies/Unregulated	Rarely	Poor	[45]

Chapter 6: Strategies for Prevention and Public Health Management

6.1 Introduction

The prevention of nephrotoxicity from herbal and traditional medicines requires a multi-pronged strategy combining regulatory reforms, patient education, health professional training, and active surveillance. Considering the global reliance on herbal remedies, especially in resource-constrained settings, these preventive strategies must be culturally sensitive and scalable.

6.2 Public Health Surveillance and Toxicovigilance

6.2.1 Strengthening Toxicovigilance Systems

Toxicovigilance refers to the proactive detection, evaluation, and prevention of toxicity from health products. Governments must:

- Integrate herbal products into adverse event reporting systems.
- Establish national herbal pharmacovigilance centers.
- Encourage mandatory reporting by healthcare professionals.

In Thailand, after integrating herbal medicine into its national pharmacovigilance system, a 40% increase in reporting of herbal-related nephrotoxic events was observed [47].

6.2.2 Establishing Herbal Toxicity Registries

Creating centralized registries can:

- Track nephrotoxic herbs and formulations.
- Help in identifying high-risk combinations.
- Facilitate regional or global alerts.

6.3 Community-Based Awareness and Education

6.3.1 Patient-Focused Campaigns

Public health departments and NGOs can conduct awareness campaigns to:

- Dispel myths like "natural equals safe."
- Highlight specific nephrotoxic herbs (e.g., Aristolochia, Aloe vera, lead-containing Rasayanas).
- Promote consultation with certified practitioners.

For example, in Kerala (India), a pilot awareness campaign on Ayurvedic nephrotoxins led to a 25% reduction in unregulated herb usage within 6 months [48].

6.3.2 School and University Integration

Inclusion of modules on herbal safety in school and undergraduate health programs can increase early awareness among future generations. Such programs should emphasize:

- Safe herbal practices
- Basic pharmacognosy
- Identifying signs of herbal toxicity

6.4 Training Healthcare Providers

Physicians, pharmacists, and alternative medicine practitioners should be trained to:

- Identify early signs of herbal nephrotoxicity
- Obtain thorough herbal usage histories from patients

- Counsel patients on herb-drug interactions and contraindications

A multicenter study in Australia found that 67% of physicians did not inquire about herbal product use unless prompted. After structured training, this number dropped to 23% [49].

6.5 Regulatory Strategies and Access Control

6.5.1 Sales Regulation

Limiting over-the-counter access to certain high-risk herbal products through:

- Prescription-only herbal categories
- Pharmacy-based sales with pharmacist oversight

6.5.2 Quality Assurance Programs

Governments and herbal companies should invest in:

- Good Manufacturing Practice (GMP) compliance
- Herbal barcoding and chemical fingerprinting
- Certification and labeling of safe formulations

For example, China's "Blue Hat" label system for licensed health products helps consumers distinguish regulated herbal supplements [50].

6.6 Herbal Product Labeling and Packaging

Clear and standardized labeling should include:

- All active herbal ingredients
- Known contraindications and side effects
- Warnings for vulnerable populations (e.g., CKD, pregnancy)
- Regulatory approval numbers

Visual symbols like kidney alert logos or color codes may enhance communication to low-literacy populations [51].

6.7 Research and Funding for Herbal Safety

6.7.1 National and International Collaboration

- Research councils should allocate funding specifically for herbal toxicity research.
- Encourage international data sharing between regulatory bodies and research centers.
- Support community-based studies on herbal practices and renal outcomes.

6.7.2 Incentivizing Safer Alternatives

- Encourage innovation in developing low-toxicity formulations.
- Promote herbal-genomic studies to predict susceptibility.

Table 6: Summary of Key Strategies to Prevent Herbal-Induced Nephrotoxicity

Strategy	Key Actions	Reference
Toxicovigilance	Mandatory AE reporting, national registries	[47]
Public Education	Campaigns, school curricula, myth busting	[48]
Healthcare Provider Training	Toxicity recognition, history taking, patient counseling	[49]
Regulation and Access Control	Prescription-only herbal lists, GMP enforcement	[50]
Labeling and Packaging	Ingredient lists, renal warnings, symbols for low literacy populations	[51]
Research and Innovation	Herbal nephrotoxicity studies, safer alternatives, funding for safety research	[52]

Chapter 7: Conclusion and Future Directions

7.1 Conclusion

Herbal and traditional medicines continue to hold significant value for millions globally, both culturally and therapeutically. However, the growing body of scientific and clinical evidence reveals a concerning link between the use of unregulated herbal products and nephrotoxicity, a public health issue that transcends borders, healthcare systems, and socioeconomic groups.

Across the chapters of this review, several key findings emerge:

- A wide range of nephrotoxic herbal agents have been identified, including *Aristolochia spp.*, Aloe vera, Senna, and heavy metal-containing Ayurvedic formulations.
- Vulnerable populations — such as the elderly, children, pregnant women, CKD patients, and those with limited health literacy — are disproportionately affected.
- Clinical cases and country-specific reports highlight real-world renal damage, ranging from acute kidney injury (AKI) to chronic kidney disease (CKD) and end-stage renal disease (ESRD).
- The regulatory environment is inconsistent, with gaps in safety evaluation, labeling, adverse event reporting, and product quality control.
- Public health strategies, including education, toxicovigilance, professional training, and labeling reforms, are critical to mitigate risk.

These conclusions underscore the urgent need for international consensus, regulatory reform, and awareness-building efforts to protect public health without undermining the legitimate role of traditional medicine in modern healthcare.

7.2 Future Directions

7.2.1 Advancing Scientific Research

There is a need to:

- Identify nephrotoxic phytochemicals through phytochemical analysis and toxicological assays.
- Develop biomarkers for early detection of herbal-induced kidney damage.
- Promote herbal-genomics research to understand individual susceptibility.

A future research priority should include longitudinal cohort studies to assess the cumulative renal impact of chronic herbal use [53].

7.2.2 Integrative Healthcare Approaches

- Integrate traditional medicine practitioners into the modern healthcare framework to ensure safer prescriptions and dosage practices.
- Promote cross-disciplinary collaboration between nephrologists, toxicologists, ethnopharmacologists, and herbalists [54].

7.2.3 Artificial Intelligence and Surveillance Tools

- Use AI to mine electronic health records and pharmacovigilance databases for early detection of adverse renal events related to herbal use.
- Incorporate AI in predicting herb–drug interactions and suggesting safer alternatives [55].

7.2.4 Global Regulatory Harmonization

- Establish an International Herbal Safety Board under the WHO or ICH to set minimum global standards.
- Develop real-time alert systems for herbal nephrotoxins, similar to those used for infectious disease outbreaks [56].

7.2.5 Patient-Centered Innovation

- Co-create herbal health tools (e.g., apps, booklets, pictograms) with community input.
- Promote low-literacy, language-diverse materials to reach rural and underserved populations [57].

Table 7. Summary of Future Directions and Implementation Goals

Focus Area	Implementation Goals	Reference
Research	Identify nephrotoxins, validate biomarkers, herbal-genomics	[53]
Integrated Health Systems	Traditional–modern collaboration, shared prescriptions	[54]
AI and Surveillance	Pharmacovigilance data mining, predictive toxicology	[55]

Focus Area	Implementation Goals	Reference
Regulatory Harmonization	Global safety standards, adverse event tracking	[56]
Patient Engagement	Co-developed tools, visual communication, rural outreach	[57]



Fig 4. Kidney

Reference

1. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. *Kidney Int*. 2008;74(2):158–69. doi:10.1038/ki.2008.103
2. World Health Organization. WHO Traditional Medicine Strategy 2014–2023. Geneva: WHO; 2013.
3. Li X, Björkman A, Wang S, et al. Herbal medicine-induced kidney injury: A systematic review and meta-analysis. Kidney Int Rep. 2020;5(8):1136–1145. doi:10.1016/j.ekir.2020.04.030
4. Tesch GH. Review: Serum and urinary biomarkers of kidney disease: A pathophysiological perspective. Nephrology (Carlton). 2010;15(6):609–16.
5. Abdualmjid R, Sergi C. Hepatotoxic botanicals–current trends and future directions. World J Gastroenterol. 2013;19(44):7420–30. doi:10.3748/wjg.v19.i44.7420
6. Yang HY, Lin JL, Chen KH, et al. Herbal medicines and acute kidney injury in hospitalized patients: a nationwide study in Taiwan. *Am J Kidney Dis*. 2012;60(3):387–95. doi:10.1053/j.ajkd.2012.02.324
7. Naicker S, Aboud O, Gharbi MB. Epidemiology of acute kidney injury in Africa. *Semin Nephrol*. 2008;28(4):348–53. doi:10.1016/j.semnephrol.2008.04.010
8. Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. *J Natl Cancer Inst*. 2010;102(3):179–86. doi:10.1093/jnci/djp467
9. Gu J, Wang Y, Wang C, et al. Triptolide-induced apoptosis in renal tubular epithelial cells via the mitochondrial pathway. *Exp Ther Med*. 2013;5(3):717–724. doi:10.3892/etm.2012.869
10. Mallick N, Khan RA. Toxicological effects of Aloe vera in Wistar albino rats. *Toxicol Ind Health*. 2016;32(10):1718–1725. doi:10.1177/0748233714568170
11. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with aristolochic acid nephropathy. *N Engl J Med*. 2000;342(23):1686–92. doi:10.1056/NEJM200006083422301
12. Saxena AK, Singh R, Kumar P, et al. Acute kidney injury due to Ayurvedic medications

containing heavy metals. *J Clin Diagn Res*. 2012;6(1):154–6.
13. Olanrewaju TO, Afolabi OT, Atiba AS. Acute kidney injury associated with herbal remedies in Nigeria: a case series. *Pan Afr Med J*. 2018;30:207. doi:10.11604/pamj.2018.30.207.15010
14. Singh NP, Ingle GK, Saini VK, et al. Chronic kidney disease of unknown etiology in agricultural communities: a public health crisis. *J Family Med Prim Care*. 2020;9(7):3417–21. doi:10.4103/jfmpc.jfmpc_1535_19
15. Perazella MA. Renal vulnerability to drug toxicity. *Clin J Am Soc Nephrol*. 2009;4(7):1275–83. doi:10.2215/CJN.05531108
16. Gao J, Liu L, Li Y, et al. Nephrotoxicity of Aloe-emodin: an in vivo study in rats. *Toxicol Mech Methods*. 2014;24(6):435–41. doi:10.3109/15376516.2014.943287
17. Liu Q. Triptolide and its expanding multiple pharmacological functions. *Int Immunopharmacol*. 2011;11(3):377–83. doi:10.1016/j.intimp.2010.12.013
18. Yang L, Li X, Jiang H, et al. Molecular mechanisms of aristolochic acid-induced renal fibrosis. *Front Pharmocol*. 2017;8:376. doi:10.3389/fphar.2017.00376
19. Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from *Teucrium chamaedrys* and *Teucrium capitatum*: two case reports. *Eur J Clin Pharmacol*. 2004;60(5):343–6. doi:10.1007/s00228-004-0779-2
20. Conn JW, Rovner DR, Cohen EL. Licorice-induced pseudo aldosteronism: Hypertension and hypokalaemia. *JAMA*. 1968;205(7):492–6.
21. Patel RM, Sarma D, Grimsley E. Oxalate nephropathy due to "juicing": Case report and review. *Am J Kidney Dis*. 2015;65(3):533–6. doi:10.1053/j.ajkd.2014.09.020
22. Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. *JAMA*. 2008;300(8):915–23. doi:10.1001/jama.300.8.915
23. Lebrun S, Mardis C, Guiot-Bresler A, et al. Acute kidney injury induced by combination of Chinese herbs and NSAIDs: a case report. *Nephrol Ther*. 2013;9(6):405–9. doi:10.1016/j.nephro.2013.08.002
24. Tang J, Liu N, Zhuang S. Role of epigenetics in kidney fibrosis. *Front Physiol*. 2021;12:660751. doi:10.3389/fphys.2021.660751
25. Bhatnagar V, Pant AB, Gupta YK, et al. Lead toxicity from Ayurvedic medicines: A report of five cases. *Indian J Med Res*. 2020;151(3):255–8. doi:10.4103/ijmr.IJMR_1271_17
26. Singh N, Singh B, Kumari R, et al. Use of alternative medicine and its impact on CKD patients in a tertiary care hospital. *Indian J Nephrol*. 2019;29(2):95–101. doi:10.4103/ijn.IJN_113_18
27. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with aristolochic acid nephropathy. *N Engl J Med*. 2000;342(23):1686–92. doi:10.1056/NEJM200006083422301
28. Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. *J Natl Cancer Inst*. 2010;102(3):179–86. doi:10.1093/jnci/djp467
29. Olowu WA, Adelusola KA, Ajayi OA. Pediatric acute tubular necrosis associated with herbal remedies in Nigeria: a case series. *J Trop Pediatr*. 2007;53(4):222–6. doi:10.1093/tropej/fmm010
30. Massawe SN, Kidanto HL, Nystrom L. Acute renal failure among eclamptic women in a tertiary hospital in Tanzania: a case series. *Afr J Reprod Health*. 2013;17(4):139–45.
31. Azadi NA, Mohammadi A, Farasatinasab M, et al. Chronic kidney disease due to herbal laxatives: a retrospective study. *Iran J Kidney Dis*. 2017;11(6):460–5.
32. Silva C, Bragança R, Teixeira J. Acute tubular necrosis associated with herbal therapy: Cat's claw (Uncaria tomentosa)

toxicity. *Nephrol Dial Transplant*. 2010;25(suppl 3):iii505.
33. Grollman AP, Jelaković B. Role of environmental toxins in endemic (Balkan) nephropathy. *J Am Soc Nephrol*. 2007;18(11):2817–23. doi:10.1681/ASN.2007050537
34. Lin J, Chen Y, Liu H, et al. Risk of chronic kidney disease associated with Chinese herbal product use in elderly individuals: a population-based study. *BMC Nephrol*. 2011;12:170. doi:10.1186/1471-2369-12-170
35. Jha V, Rathi M, Gupta KL. Herbal medicine use in chronic kidney disease: a double-edged sword. *Indian J Nephrol*. 2020;30(5):309–15. doi:10.4103/ijn.IJN_383_19
36. Olowu WA, Adelusola KA, Ajayi OA. Pediatric acute tubular necrosis associated with herbal remedies in Nigeria: a case series. *J Trop Pediatr*. 2007;53(4):222–6. doi:10.1093/tropej/fmm010
37. Ghosh AK, Bajaj R. Study on awareness and practice of herbal medicine use in rural India. *Asian J Pharm Clin Res*. 2018;11(3):314–8.
38. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Front Pharmacol*. 2014;4:177. doi:10.3389/fphar.2013.00177
39. WHO Traditional Medicine Strategy 2014–2023. Geneva: World Health Organization; 2013. Available from: https://apps.who.int
40. WHO Traditional Medicine Strategy 2014–2023. World Health Organization. Geneva: WHO; 2013.
41. U.S. Food and Drug Administration (FDA). Dietary Supplement Health and Education Act of 1994. [Accessed online] https://www.fda.gov
42. European Medicines Agency (EMA). Regulation of Herbal Medicinal Products in the EU. Available from: https://www.ema.europa.eu
43. Ministry of AYUSH, Government of India. Guidelines for Ayurvedic Drug Development. [Accessed online] https://www.ayush.gov.in
44. Liang QL, Wang Y, Jin Y, et al. Current situation and perspectives of traditional Chinese medicine regulations in China. *Chin Med*. 2020;15(1):102. doi:10.1186/s13020-020-00347-z
45. Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health: an ethical analysis. *Bull World Health Organ*. 2008;86(8):594–9. doi:10.2471/BLT.07.042820
46. Gurley BJ, Swain A, Hubbard MA, et al. Clinical implications of herb–drug interactions: an update. *Drug Metab Rev*. 2012;44(2):147–62. doi:10.3109/03602532.2012.661410
47. Suwanpimolkul G, Chentanez V, Tankanitlert U. Impact of integrating herbal medicines into Thailand's pharmacovigilance system. *Drug Saf*. 2015;38(3):219–27. doi:10.1007/s40264-014-0260-5
48. Nair S, Sreedharan R. Community awareness campaign on herbal nephrotoxicity in rural Kerala: a pilot project. *Indian J Public Health*. 2019;63(4):315–8. doi:10.4103/ijph.IJPH_116_19
49. Barnes J, Anderson LA, Phillipson JD. Herbal medicines and adverse drug interactions: a survey of Australian physicians. *Clin Pharmacol Ther*. 2009;86(4):494–7. doi:10.1038/clpt.2009.162
50. State Administration for Market Regulation (China). Guidelines on health food registration. Available from: http://www.samr.gov.cn
51. Joshi A, Prasad S, Mahapatra S. Improving herbal drug safety: visual warning systems and literacy-sensitive labeling. *J Ethnopharmacol*. 2020;256:112780. doi:10.1016/j.jep.2020.112780
52. Rajasekaran A, Aravind A, Thangavel S. Trends in nephrotoxicity-focused herbal pharmacological research. *Phytomedicine*.

2023;112:154701. doi:10.1016/j.phymed.2023.154701
53. Schmidlin T, Gervaz P, Hilty M, et al. Long-term renal impact of chronic herbal drug consumption: need for large-scale cohort studies. *Clin Nephrol*. 2022;97(6):301–9. doi:10.5414/CN110843
54. Tilburt JC, Kaptchuk TJ. Integrative medicine and the future of health care: ethical perspectives. *Acad Med*. 2008;83(3):176–80. doi:10.1097/ACM.0b013e318163cd62
55. Rajalakshmi P, Iyer A, Nareshkumar M. AI-enabled detection of nephrotoxicity signals from herb–drug interactions. *BMC Med Inform Decis Mak*. 2021;21(1):76. doi:10.1186/s12911-021-01455-2
56. Maegawa T, Kim J, Sasaki K. Proposal for an international early alert system for herbal-induced nephrotoxicity. *Regul Toxicol Pharmacol*. 2020;116:104738. doi:10.1016/j.yrtph.2020.104738
57. Jaiswal M, Dasgupta A, Sinha D. Designing herbal safety materials for rural populations: pictogram-based approaches. *Health Educ Res*. 2019;34(1):78–86. doi:10.1093/her/cyy050